Summary:
Overall survival of patients treated with the doublet carboplatin plus weekly paclitaxel versus single agent therapy (IFCT 0501). Single-arm (n=226): median survival (95% CI) 6.2 (5.3–7.4) months; 1-year survival 25.4% (19.9–31.3%). Doublet arm (n=225): median survival 1.03 (8.3–12.6) months; 1-year survival 44.5% (37.9–50.9%). HR: hazard ratio. Reproduced and modified from [14] with permission from the publisher.
Type:
Figure
Sub Component:
Normal
Slug:
F23
Highwire: Type:
fragment
Highwire: Parent:
HighWire: Journal/Corpus Code:
ersbk
Highwire: pisa_id:
ersbk;9781849840620/1/chapter_16/F23
Highwire: pisa_master:
ersbk;9781849840620/1/chapter_16/F23
HighWire: Atom Path:
/ersbk/9781849840620/9781849840620/SEC20/F23.atom
Highwire: cpath:
/content/9781849840620/9781849840620/SEC20/F23
Image - Large:
Highwire: cpathalias:
/content/ersbk/9781849840620/9781849840620/SEC20/F23
Image - Medium:
Highwire: Variants:
expansion
Image - Small:
Highwire: State:
Released
Contributors:
<atom:author xmlns:atom="http://www.w3.org/2005/Atom" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:nlm="http://schema.highwire.org/NLM/Journal" hwp:inherited="yes" nlm:contrib-type="author"><atom:name>Charlotte Leduc</atom:name><nlm:name name-style="western" hwp:sortable="Leduc Charlotte"><nlm:surname>Leduc</nlm:surname><nlm:given-names>Charlotte</nlm:given-names></nlm:name></atom:author>
<atom:contributor xmlns:atom="http://www.w3.org/2005/Atom" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:nlm="http://schema.highwire.org/NLM/Journal" hwp:inherited="yes" nlm:contrib-type="author"><atom:name>Elisabeth Quoix</atom:name><atom:email>elisabeth.quoix@chru-strasbourg.fr</atom:email><nlm:name name-style="western" hwp:sortable="Quoix Elisabeth"><nlm:surname>Quoix</nlm:surname><nlm:given-names>Elisabeth</nlm:given-names></nlm:name></atom:contributor>
Last load event:
Monday, January 10, 2022 - 17:39